Biogen Agrees To Pay $22 Mln To Settle Kickback Allegations WESTON (dpa-AFX) - Biogen has agreed to pay $22 million to settle allegations that it illegally using foundations as a conduit to pay the copays of Medicare patients taking the company's multiple sclerosis drugs, the U.S. Justice Department said. Advanced Care Scripts, a pharmacy company that worked with Biogen, agreed to pay $1.4 million to settle the allegation. The whistleblower will receive about $3.96 million of the settlement, the Justice department said. Under the Anti-Kickback Statute, a pharmaceutical company is prohibited from offering or paying, directly or indirectly, any remuneration-which includes money or any other thing of value- to induce Medicare patients to purchase the company's drugs.